Desentum, a biopharmaceutical company based in Espoo, Finland, has announced a significant funding round of €12M to further the clinical development of its birch pollen allergy vaccine, DM-101PX. The investment was led by Springvest Oyj, a Finnish investment firm dedicated to supporting the growth of innovative companies.